Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Residual Lesional Gene Expression in Psoriasis Patients with Complete Skin Clearance Treated with Guselkumab or Adalimumab in VOYAGE 1 and 2.
Blauvelt A, Gordon KB, Langley RG, Branigan PJ, Chen Y, Miller M, Han C, Fakharzadeh S, Muñoz-Elías EJ, Armstrong AW. Blauvelt A, et al. Among authors: langley rg. J Invest Dermatol. 2024 Dec;144(12):2816-2819.e2. doi: 10.1016/j.jid.2024.05.020. Epub 2024 Jun 25. J Invest Dermatol. 2024. PMID: 38936766 Free article. No abstract available.
Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy.
Blauvelt A, Chen Y, Branigan PJ, Liu X, DePrimo S, Keyes BE, Leung M, Fakharzadeh S, Yang YW, Muñoz-Elías EJ, Krueger JG, Langley RG. Blauvelt A, et al. Among authors: langley rg. JID Innov. 2024 Jun 26;4(5):100297. doi: 10.1016/j.xjidi.2024.100297. eCollection 2024 Sep. JID Innov. 2024. PMID: 39224116 Free PMC article.
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Langley RG, et al. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. N Engl J Med. 2014. PMID: 25007392 Free article. Clinical Trial.
Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline Psoriasis Area and Severity Index from week 4 to 40.
Langley RG, Sanyal C, Situ A, Alulis S, Hassan F, Peterson S, Teneralli RE, Lee J, Patel BP, Disher T. Langley RG, et al. JAAD Int. 2024 Jan 19;15:165-167. doi: 10.1016/j.jdin.2023.12.012. eCollection 2024 Jun. JAAD Int. 2024. PMID: 38882038 Free PMC article. No abstract available.
Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensus.
Torres T, Brembilla NC, Langley RG, Warren RB, Thaçi D, Kolios AGA, Prinz JC, Londono-Garcia A, Nast A, Santin M, Goletti D, Abreu M, Spuls P, Boehncke WH, Puig L. Torres T, et al. Among authors: langley rg. J Eur Acad Dermatol Venereol. 2025 Jan;39(1):52-69. doi: 10.1111/jdv.20287. Epub 2024 Aug 16. J Eur Acad Dermatol Venereol. 2025. PMID: 39149807 Review.
Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.
Burshtein J, Shah M, Zakria D, Armstrong AW, Golant AK, Gottlieb AB, Weinberg JM, Kircik L, Han G, Langley RG, Neimann AL, Lebwohl M. Burshtein J, et al. Among authors: langley rg. J Drugs Dermatol. 2024 Aug 1;23(8):592-599. doi: 10.36849/JDD.8246. J Drugs Dermatol. 2024. PMID: 39093660 Review.
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
Papp KA, Gooderham M, Lynde C, Brassard D, Al-Mohammedi F, Prajapati VH, Delorme I, Albrecht L, Haydey R, Alam MS, Beecker J, Siddha S, Maguin M, Farag MS, Vieira A, Rihakova L, Langley RG. Papp KA, et al. Among authors: langley rg. Arch Dermatol Res. 2024 Jun 8;316(7):362. doi: 10.1007/s00403-024-03122-w. Arch Dermatol Res. 2024. PMID: 38850346 Free PMC article.
Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study.
Magnolo N, Cameron MC, Shahriari M, Geng B, Calimlim BM, Teixeira H, Hu X, Yang Y, Liu Y, Zhang S, Sancho Sanchez C, Altman K, Langley RG. Magnolo N, et al. Among authors: langley rg. J Dermatolog Treat. 2024 Dec;35(1):2344589. doi: 10.1080/09546634.2024.2344589. Epub 2024 May 2. J Dermatolog Treat. 2024. PMID: 38697950 Free article. Clinical Trial.
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.
Papp K, Warren RB, Green L, Reich K, Langley RG, Paul C, Asahina A, Johnson L, Arora V, Osuntokun O, Lebwohl M. Papp K, et al. Among authors: langley rg. Lancet Rheumatol. 2023 Sep;5(9):e542-e552. doi: 10.1016/S2665-9913(23)00120-0. Epub 2023 Aug 21. Lancet Rheumatol. 2023. PMID: 38251498 Clinical Trial.
192 results